계정 가입
email 로 로그인
email 로 가입
수신함을 확인하세요
OncoResponse
About
OncoResponse is a company providing cancer research into immunotherapies and the newest technologies for oncologists.
- 1 - 10
Details
- Last Funding Type
- Series C
- Last Funding Money Raised
- $40.60M
- Industries
- Biopharma,Biotechnology,Health Care,Therapeutics
- Founded date
- Jan 1, 2016
- Number Of Employee
- 1 - 10
- Operating Status
- Active
OncoResponse Inc., an immuno-oncology company located in Houston, Texas, has partnered with MD Anderson Cancer Center (MDACC) to deploy a unique and transformational approach to cancer therapeutic monoclonal antibody and target discovery. The company licensed the I-STAR™ platform, developed and validated by Theraclone Sciences of Seattle, to interrogate the human memory B-cell repertoire of cancer patients who are considered “Elite Responders” to immunotherapy; as such, their own adaptive immune system responded to immunotherapy stimulation in a way that achieved curative or durable responses. From these Elite Responders, OncoResponse is leveraging the human immune system to identify fully human monoclonal antibodies and discover novel targets that will lead to the development of fully human antibody derived therapeutics for the treatment of cancer.
Funding Rounds
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Mar 31, 2021 | Series C | $40.60M | 1 | — | — | Detail |
| Sep 11, 2018 | Series B | $40M | 1 | — | — | Detail |
| May 7, 2016 | Series A | $12.50M | 1 |
ARCH Venture Partners
|
— | Detail |
Investments
|
Date
Company Name
|
Round | Money Raised | Industry | Lead Investor |
|---|---|---|---|---|
|
Dec 13, 2016
Ember Technologies
|
Series B | $5.96M | Consumer Electronics | — |
Investors
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
ARCH Venture Partners
|
— | Series C |
